公开(公告)号：US11873298B2

公开(公告)日：2024-01-16

申请号：US16758495

申请日：2018-10-24

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： Matthew Lucas ,  Bertrand Le Bourdonnec ,  Iwona Wrona ,  Bhaumik Pandya ,  Parcharee Tivitmahaisoon ,  Kerem Ozboya ,  Benjamin Vincent ,  Daniel Tardiff ,  Jeff Piotrowski ,  Eric Solis ,  Robert Scannevin ,  Chee-Yeun Chung ,  Rebecca Aron ,  Kenneth Rhodes

IPC: C07D413/14 ,  C07D271/07 ,  C07D413/04 ,  C07D413/10 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10

CPC classification number: C07D413/14 ,  C07D271/07 ,  C07D413/04 ,  C07D413/10 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10

Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

公开(公告)号：US11873288B2

公开(公告)日：2024-01-16

申请号：US17112713

申请日：2020-12-04

Applicant: The Regents of the University of California

Inventor： Bruce Hammock ,  Sean Kodani

IPC: C07D401/06 ,  C07C275/28 ,  C07D271/10 ,  C07C275/34 ,  A61P35/00 ,  C07C275/36 ,  C07D211/16 ,  C07D211/46 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D417/04

CPC classification number: C07D401/06 ,  A61P35/00 ,  C07C275/28 ,  C07C275/34 ,  C07C275/36 ,  C07D211/16 ,  C07D211/46 ,  C07D271/10 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D417/04 ,  C07C2601/14

Abstract: The present invention provides compounds that are dual inhibitors of soluble epoxide hydrolase and fatty acid amide hydrolase. The present invention also provides methods of using the compounds to inhibit soluble epoxide hydrolase and fatty acid amide hydrolase, and to treat cancer.

公开(公告)号：US20240002373A1

公开(公告)日：2024-01-04

申请号：US18342321

申请日：2023-06-27

Applicant: Blacksmith Medicines, Inc.

Inventor： Min TENG ,  Baskar NAMMALWAR ,  David T. PUERTA

IPC: C07D413/14

CPC classification number: C07D413/14

Abstract: Provided herein is an LpxC inhibitor compound, as well as methods of making and pharmaceutical compositions comprising said compound, and methods of use thereof in the treatment of disease that would benefit from treatment with an LpxC inhibitor, including gram-negative bacterial infections such as urinary tract infections and the like.

公开(公告)号：US20240002359A1

公开(公告)日：2024-01-04

申请号：US18254190

申请日：2021-12-01

Applicant: Stephane L. BOGEN ,  Ping CHEN ,  Dane James CLAUSSEN ,  Xianhai HUANG ,  Michael T. RUDD ,  Shawn P. WALSH ,  Lan WEI ,  Dexi YANG ,  Merck Sharp & Dohme LLC

Inventor： Stephane L. Bogen ,  Ping Chen ,  Dane James Claussen ,  Xianhai Huang ,  Michael T. Rudd ,  Shawn P. Walsh ,  Lan Wei ,  Dexi Yang

IPC: C07D401/04 ,  C07D417/04 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D401/04 ,  C07D417/04 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention is directed to 3-heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

公开(公告)号：US11858946B2

公开(公告)日：2024-01-02

申请号：US17306008

申请日：2021-05-03

Applicant: The Board of Trustees of the University of Illinois

Inventor： Paul J. Hergenrother ,  Michelle Richter ,  Andrew Riley ,  Bryon S. Drown ,  Martin Chavez ,  Sarah Tasker ,  Alfredo Garcia

IPC: C07D413/14 ,  C07D413/04 ,  C07D413/10 ,  C07D471/04 ,  C07D471/14 ,  C07D498/04 ,  A61P31/04 ,  C07D413/12 ,  C07D491/052 ,  C07D407/06 ,  C07D407/12 ,  C07C225/20 ,  C07D471/20 ,  C07D263/20 ,  C07J1/00 ,  C07J13/00 ,  C07J21/00 ,  C07J41/00 ,  C07J43/00 ,  C07J73/00 ,  C07D417/12

CPC classification number: C07D491/052 ,  A61P31/04 ,  C07C225/20 ,  C07D263/20 ,  C07D407/06 ,  C07D407/12 ,  C07D413/04 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/14 ,  C07D471/20 ,  C07D498/04 ,  C07J1/0011 ,  C07J13/007 ,  C07J21/008 ,  C07J41/0011 ,  C07J41/0055 ,  C07J41/0088 ,  C07J43/003 ,  C07J73/00 ,  C07C2603/82

Abstract: Disclosed are novel compounds that accumulate in Gram-negative bacteria. Also disclosed are method of antimicrobial treatment using the compounds.

公开(公告)号：US11858929B2

公开(公告)日：2024-01-02

申请号：US17176855

申请日：2021-02-16

Applicant: NOVITA PHARMACEUTICALS, INC. ,  CORNELL UNIVERSITY

Inventor： Xin-Yun Huang ,  Christy Young Shue

IPC: C07D471/04 ,  C07D209/30 ,  C07D209/40 ,  C07D231/56 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D405/12 ,  C07D405/04

CPC classification number: C07D471/04 ,  C07D209/30 ,  C07D209/40 ,  C07D231/56 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: Provided are compounds, compositions and methods for inhibiting fascin activity or treating a condition or disorder mediated by fascin activity in a subject in need thereof.

公开(公告)号：US11858916B2

公开(公告)日：2024-01-02

申请号：US17251929

申请日：2019-06-13

Applicant: Pfizer Inc.

Inventor： Gary Erik Aspnes ,  Scott W. Bagley ,  Edward L. Conn ,  John M. Curto ,  David J. Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David A. Griffith ,  Kim Huard ,  Chris Limberakis ,  Alan M. Mathiowetz ,  David W. Piotrowski ,  Roger B. Ruggeri

IPC: C07D405/14 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D405/14 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04

Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20230416263A1

公开(公告)日：2023-12-28

申请号：US18058549

申请日：2022-11-23

Applicant: Epizyme, Inc.

Inventor： Richard Chesworth ,  Oscar Miguel Moradei ,  Gideon Shapiro ,  Lei Jin ,  Robert E. Babine

IPC: C07D487/10 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D239/42 ,  C07D409/14 ,  C07D413/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/08 ,  C07D493/04 ,  C07D493/10 ,  C07D495/04 ,  C07D498/04 ,  C07D498/10 ,  C07D413/04 ,  C07D487/04

CPC classification number: C07D487/10 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D239/42 ,  C07D409/14 ,  C07D413/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/08 ,  C07D493/04 ,  C07D493/10 ,  C07D495/04 ,  C07D498/04 ,  C07D498/10 ,  C07D413/04 ,  C07D487/04

Abstract: Provided herein are compounds of Formula (I):




and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula:




wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

公开(公告)号：US20230416238A1

公开(公告)日：2023-12-28

申请号：US18319719

申请日：2023-05-18

Applicant: Hoffmann-La Roche Inc.

Inventor： Xianfeng LIN ,  Hongying YUN ,  Bo ZHANG ,  Xiufang ZHENG

IPC: C07D413/04 ,  C07D413/14 ,  C07D409/14

CPC classification number: C07D413/04 ,  C07D409/14 ,  C07D413/14

Abstract: The present invention provides novel compounds having the general formula:






wherein A1 to A4, X, Cy and R1 are as described herein, compositions including the compounds and methods of using the compounds.

公开(公告)号：US20230416226A1

公开(公告)日：2023-12-28

申请号：US17998552

申请日：2021-05-20

Applicant: SIRONAX LTD.

Inventor： Zhaolan ZHANG ,  Zhiyuan ZHANG ,  Yaning SU ,  Yanping XU

IPC: C07D401/14 ,  C07D403/14 ,  C07D417/14 ,  C07D413/14 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: Provided are azetidine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the persons health or condition.